APIs pour la recherche et les impuretés

N-Cyano-N'-methyl-N''-[2-[(5-methyl-1H-imidazol-4-yl)methylsulphinyl]ethyl]guanidine is an acetylcholinesterase inhibitor that is used to treat Alzheimer's disease. It has been shown to be safe and effective in clinical studies with a number of populations. The drug binds to the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. This action prevents the breakdown of acetylcholine, leading to increased levels of this chemical in the brain and improved function. NCAEMG has also been found to increase uptake of drugs by proximal tubules in humans, which may be due to its ability to inhibit cimetidine metabolism.

Imatinib is a kinase inhibitor that inhibits the kinase activity of tyrosine-protein phosphatase receptor (c-Abl) and platelet-derived growth factor receptor (PDGFR), which are both involved in tumor cell proliferation. Imatinib has been shown to be effective in treating leukemia and other types of cancer, as well as regulating the production of cytokines and protein tyrosine phosphatases. It is also being studied for use in Alzheimer's disease. Imatinib has selectivity for c-Abl over PDGFR, which makes it an attractive drug candidate for cancer therapy.